Home HOME Neoplasma 2015 Neoplasma Vol.62, No.2, p.278-287, 2015

Journal info


6 times a year.
Founded: 1954
ISSN 0028-2685
ISSN 1338-4317 (online)

Published in English

Editorial Info
Abstracted and Indexed
Submission Guidelines

Select Journal







Webshop Cart

Your Cart is currently empty.

Info: Your browser does not accept cookies. To put products into your cart and purchase them you need to enable cookies.

Neoplasma Vol.62, No.2, p.278-287, 2015

Title: Clinical significance of ERG rearrangement subtype and its association with increased p53 expression in Japanese and German prostate cancer
Author: J. NISHIJIMA, T. HARA, K. IKEMOTO, A. OGA, K. KOBAYASHI, Y. KAWAI, H. MATSUMOTO, K. NAGAO, K. SASAKI, V. GKOLEIZAKIS, J. FICHTNER, H. MATSUYAMA

Abstract:

This study investigated differences in prevalence of the androgen-regulated transmembrane protease serine 2 (TMPRSS2) and ETS transcription factor family member, v-ets erythroblastosis virus E26 oncogene homolog (ERG) fusion gene (TMPRSS2-ERG fusions) in clinically localized prostate cancer Japanese and German patients. A total of 105 specimens, including 69 Japanese and 36 German patients, were collected. The status of TMPRSS2-ERG fusion was determined by fluorescence in situ hybridization, and correlations of the TMPRSS2-ERG fusion with clinicopathological characteristics and immunohistochemistry were studied.

Gene fusions were identified in 20% (14/69) of Japanese and 53% (19/36) of German patients (P < 0.001).

The difference in the type of gene fusion between the two ethnic groups was statistically significant (P=0.024).

Overexpression of ERG protein was significantly associated with gene fusion. Biochemical recurrence was significantly higher in patients with ERG overexpression than in those without, and not related to TMPRSS2-ERG fusion status. Interestingly, two types of gene fusions (deletion and increase of copy number) were significantly associated with increased p53 expression (P = 0.005).

Association of specific gene fusions harboring higher genomic alterations with p53 expression levels suggests that p53 mutation might drive more aggressive arrangements of TMPRSS2-ERG fusion in prostate cancer.



Keywords: ERG, p53, prostate cancer, TMPRSS2-ERG fusion
Published online: 14-Jan-2015
Year: 2015, Volume: 62, Issue: 2 Page From: 278, Page To: 287
doi:10.4149/neo_2015_033


download file



© AEPress s.r.o
Copyright notice: For any permission to reproduce, archive or otherwise use the documents in the ELiS, please contact AEP.